2024
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA 2024, 332 PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.Peer-Reviewed Original Research
2017
The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment
Viola A, Balsamo L, Neglia JP, Brouwers P, Ma X, Kadan-Lottick NS. The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. Journal Of Pediatric Hematology/Oncology 2017, 39: 174-178. PMID: 28085741, PMCID: PMC5364064, DOI: 10.1097/mph.0000000000000761.Peer-Reviewed Original ResearchConceptsLeukemia survivorsNeurocognitive impairmentAttention-deficit/hyperactivity disorder (ADHD) outcomesPediatric acute lymphoblastic leukemia survivorsPediatric acute lymphoblastic leukemia treatmentAcute lymphoblastic leukemia survivorsAcute lymphoblastic leukemia treatmentPotential late effectsAcute lymphoblastic leukemiaMultivariate logistic regressionExecutive Function Parent FormCross-sectional studyOngoing clinical careBehavior Rating InventoryComprehensive neuropsychological assessmentElevated scoresFirst remissionClinical outcomesLymphoblastic leukemiaLate effectsClinical careRating InventoryLeukemia treatmentCognitive impairmentIndex score